

*B1*  
activity comprising a pharmacological carrier and an anti-inflammatory effective  
amount of a peptide having the formula f-Met-Leu-Phe-Phe [f-Met-Leu-X, wherein X is  
selected from the group consisting of Tyr, Tyr-Phe, Phe-Phe and Phe-Tyr].

---

Please cancel claims 2 and 3.

Please add the following new claims 24-31.

---

*B2*  
--24. The pharmaceutical composition of claim 1, wherein the anti-inflammatory activity is due to inhibition of mast cell degranulation.

25. The pharmaceutical composition of claim 1, wherein the anti-inflammatory activity is due to reduction of adhesion, migration and aggregation of lymphocytes, eosinophils and neutrophils to a site of inflammation.

26. The pharmaceutical composition of claim 1, wherein the anti-inflammatory activity is due to inhibition of the release of cytokines.

27. The pharmaceutical composition of claim 1, wherein the anti-inflammatory activity is due to inhibition of the release of histamines.

28. The pharmaceutical composition of claim 1, wherein the anti-inflammatory activity is due to inhibition of the release of leukotrienes.

29. The pharmaceutical composition of claim 1, wherein the inflammation is due to asthma.

30. The pharmaceutical composition of claim 1, wherein the inflammation is due to arthritis.

b2  
concl  
31. The pharmaceutical composition of claim 1, wherein the inflammation is due to anaphylaxis.--

---

**REMARKS**

In the Office Action dated January 12, 2000, claims 1-23 are pending, claims 9-23 are withdrawn from consideration, and claims 1-8 are rejected. Claim 1 has been amended to more particularly point out and distinctly claim the subject matter regarded as invention. New claims 24-31 have been added. No new matter has been added by virtue of the amendments or claim additions. Support for the amendments and additions can be found throughout the specification including the description and the claims as originally filed. In particular, see the Summary of the Invention at pages 6-7.

Reference is made to the accompanying Declaration under 37 CFR §1.132 by James Clagett which is being submitted along with this amendment.